Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply.
| Autor: | De Savi C; Kymera Therapeutics, 300 Technology Square, Second Floor, Cambridge, Massachusetts 02139, United States., Hughes DL; Cidara Therapeutics, Inc., 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, United States., Kvaerno L; Hypha Discovery Ltd, 154C Brook Drive, Milton Science Park, Abingdon OX14 4SD, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Organic process research & development [Org Process Res Dev] 2020 Jun 02; Vol. 24 (6), pp. 940-976. Date of Electronic Publication: 2020 Jun 02 (Print Publication: 2020). |
| DOI: | 10.1021/acs.oprd.0c00233 |
| Abstrakt: | The outbreak of the COVID-19 pandemic has spurred an intense global effort to repurpose existing approved drugs for its treatment. In this review, we highlight the development of seven small-molecule drugs that are currently being assessed in clinical trials for the treatment of COVID-19. Three sections are presented for each drug: (1) history, mechanism of action, and status of clinical trials; (2) scalable synthetic routes and final forms; and (3) outlook for supply should clinical trials show treatment efficacy. A brief overview of diagnostic testing and vaccine development is also presented. Competing Interests: The authors declare no competing financial interest. (Copyright © 2020 American Chemical Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|